Open AccessTREATMENT WITH THE CHIMERIC ANTI-IL-2Rα ANTIBODY BASILIXIMAB (SIMULECT®) AFFECTS BOTH THE IL-2 AND THE IL-15 SIGNALING PATHWAY AFTER CLINICAL KIDNEY TRANSPLANTATION.
Author(s) -
Carla C. Baan,
I. C. van Riemsdijk,
M.J.A.M Boelaars-van Haperen,
Jan N.M. IJzermans,
Willem Weimar
Publication year - 2000
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/00007890-200004271-00570
Subject(s) - basiliximab , transplantation , kidney transplantation , medicine , immunology , cancer research